
This full video presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida features Dr. Eric Simpson, Dr. Shawn Kwatra, Dr. Jason Hawkes and Dr. Victoria Werth. The faculty present the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
Join the effort to improve CRSwNP care. World Anosmia Day serves as an opportunity to raise awareness about the loss of the sense of smell. Access some of countless educational resources with ADVENT below.

This podcast episode looks at the epidemiology, clinical presentation and classification of atopic dermatitis of the hand and feet and the impact it has on patients' quality of life.

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Brian Kim discuss the burdensome itch in prurigo nodularis, the multifactorial etiology of the disease, and the multiple pathological factors that contribute to chronic itch and skin inflammation in PN.
Join experts Dédée Murrell, Donna Aline Culton, Joost Meijer and Enno Schmidt for an educational presentation on the clinical presentation, disease burden, diagnosis, and underlying pathophysiology of bullous pemphigoid (BP). Dive deeper into unmet needs and treatment challenges faced by these patients and how targeted therapies may address them.
In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Vibeke Backer discusses how Type 2 inflammation drives severe, uncontrolled CRSwNP. It covers key immune cells and biomarkers (e.g., IL-4, IL-5, IL-13, TSLP), global prevalence differences, and the importance of symptom tracking and targeted therapies.

Dr. Stephanie Christenson discusses the association between COPD exacerbations and the increased risks of morbidity and mortality

Dr. Mario Castro discusses how COPD exacerbations can predict future exacerbations and lead to progressive lung function loss in COPD patients.

Join experts G. Walter Canonica, Vibeke Backer, and Joaquim Mullol for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.
Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.
Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.